



Search



- Home
- About Abbott
- Products
- Global Citizenship
- Careers
- [Newsroom](#)
- [Press Releases](#)
- Feature Stories
- Conferences & Events
- Fact Sheets
- Media Contacts & News Sites
- Leadership Team
- Rankings & Honors
- Follow Us
- Media Library
- Set Up E-mail Alerts
- Press Kit - Separation
- Investor Relations
- Partnerships



## PRESS RELEASE

### New Abbott Test Available in Europe Provides Novel Tool to Aid Doctors in Evaluati

Innovative test may help clinicians reduce time in diagnosing heart attacks and assist heart attacks

January 09, 2013

Abbott Park, Illinois ([NYSE: ABT](#)) — An estimated 17 million people throughout the world die attacks or strokes.<sup>1</sup> Time is a critical factor in diagnosing and treating people who may be having heart attacks sooner, Abbott announced today CE Marking (Conformité Européenne) -I Assay.

#### Diagnosing Potential Heart Attacks

The preferred biomarker used to identify suspected heart attacks is cardiac troponin, a protein injury to the heart.<sup>2</sup> Many patients who visit the emergency room with chest pain complaints and samples drawn for troponin tests upon admission, after 6 hours, and then potentially 12 hours who are having a heart attack, the length of time to diagnosis is a crucial factor because the heart is not receiving blood, and eventually, almost all the affected parts of the heart could be irreversibly

Abbott's new ARCHITECT STAT High Sensitive Troponin-I Assay can measure very low levels whether or not patients are having a heart attack within 2 to 4 hours.<sup>4</sup> This faster evaluation can lead to treatment by several hours when compared to standard troponin tests.

"The advantage of high sensitive troponin tests compared to current tests is that clinicians may diagnose heart attack much sooner and with higher accuracy compared to contemporary tests," said Professor Dr. Jochen Bauert, University Heart Center of Hamburg, Germany. "This is important information for patient care and may lead to less invasive therapy and discharge a patient earlier."

#### Determining Risk for Future Cardiovascular Events

Another concern for patients who have experienced symptoms of a heart attack or who suffer from risk for experiencing a second cardiac event or heart attack within a few weeks or months. Ask your doctor to determine if patients are at risk to suffer from cardiovascular events 30 days and 90 days after a heart attack.

"The sooner a patient can be diagnosed with a cardiac event, the faster a patient can get the treatment they need," said Dr. Jochen Bauert, vice president, Diagnostics Products, Abbott. "Abbott's new high sensitive troponin test is an important step in quickly, potentially improving the way heart attacks are diagnosed for patients around the world."

The new assay runs on Abbott's fully-automated ARCHITECT family of analyzers and is available pending country registration.

#### INTENDED USE

The ARCHITECT STAT High Sensitive Troponin-I assay is a chemiluminescent microparticle immunoassay for the determination of cardiac troponin I (cTnI) in human plasma and serum on the ARCHITECT STAT High Sensitive Troponin-I assay. The ARCHITECT STAT High Sensitive Troponin-I assay is used as an aid in the diagnosis of myocardial infarction (MI) and to aid in the assessment of mortality and major adverse cardiac events (MACE) consisting of myocardial infarction, revascularization, and death. The ARCHITECT STAT High Sensitive Troponin-I assay is not intended for use in patients with symptoms suggestive of acute coronary syndrome (ACS).

## About Cardiovascular Diseases

According to the World Health Organization (WHO), by 2030 almost 25 million people will die from cardiovascular diseases, major disease and stroke. Cardiovascular diseases are projected to remain the single leading cause of death.<sup>5</sup>

## About Abbott Diagnostics

Abbott is a global leader in *in vitro* diagnostics and offers a broad range of innovative instrument systems and tests for hospital, molecular labs, blood banks, physician offices and clinics. With more than 22,000 customers in more than 100 countries, Abbott products offer customers automation, convenience, bedside testing, cost effectiveness, and flexibility. Abbott has helped transform medical diagnosis from an art to a science through the company's commitment to improving patient care and lowering costs.

## About Abbott

Abbott (NYSE: [ABT](#)) is a global healthcare company devoted to improving life through the development of products and technology breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritional and brand pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 70,000 people.

Visit Abbott at [www.abbott.com](http://www.abbott.com) and connect with us on Twitter at [@AbbottNews](#).

---

1 Cardiovascular Diseases Fact Sheet No 317. World Health Organization, September 2012.

Web site: [www.who.int/mediacentre/factsheets/fs317](http://www.who.int/mediacentre/factsheets/fs317).

2 Thygesen K, Alpert JS, Jaffe AS et al. Third universal definition of myocardial infarction. *European Heart Journal*. 2012; 33:2568-2576.

3 Thygesen K, Alpert JS, White HD et al. Universal definition of myocardial infarction. *European Heart Journal*. 2007; 28:2525-2538.

4 Abbott ARCHITECT STAT High Sensitive Troponin-I Product Insert (PI), January 2013.

Web site: [www.who.int/mediacentre/factsheets/fs317](http://www.who.int/mediacentre/factsheets/fs317).

5 Cardiovascular Diseases Fact Sheet No 317. World Health Organization, September 2012.

---

### Media:

Darcy Ross (847) 937-3655

Jessica Masuga (847) 935-0650

### Financial:

Tina Ventura (847) 935-9390

---

## ARTICLE TOOLS

 Connect with us on Twitter at [@AbbottNews](#)

[Feature Stories](#)

[ShareThis](#)

 [RSS Feeds](#)